UTRN and Duchenne muscular dystrophy: In this article, in vitro and in vivo preclinical applications of these three NHEJ methods will be discussed, in addition to other recent advancements in CRISPR therapeutics for DMD such as base editing, prime editing, and utrophin upregulation.